Newsletter_02-2024_EN

Leveraging collaboration opportunities to continue to deliver ultra-high-quality
products and services while achieving growth ambitions.
Cherwell Joins the AnalytiChem
Group of Companies
Cherwell, cleanroom microbiology solutions expert, is excited to announce
it is joining the AnalytiChem group of companies. Cherwell
will join seven other businesses within the group, located across Europe,
North America and Australia.
Cherwell was founded in 1971 and serves customers across the
UK and internationally with a range of products and solutions focused
on environmental and process monitoring within pharmaceutical
manufacturing. Cherwell will continue to operate from its
location in Bicester (Oxford), UK and continue to be led by Andy
Whittard, the current Managing Director.
Andy Whittard stated: “AnalytiChem shares our vision for
growth, philosophy, culture, market approach and guarantees the
continuity of Cherwell as a provider of ultra-high-quality products
and services. Within the AnalytiChem group, Cherwell will be able
to leverage collaboration opportunities, especially with our new
sister company bioTrading, alongside our focused offering of environmental
and process monitoring products to the pharmaceutical
manufacturing sector. Together with the great team at Cherwell we
look forward to the exciting next steps in the development of the
company.”
Andy Whittard, Managing Director, Cherwell
Raoul Biskupek, Group CEO at AnalytiChem adds, “As AnalytiChem
we are focused on highest quality capabilities for the benefit of our
customer base, something Cherwell clearly demonstrates with its
focused portfolio manufactured in Bicester and services provided
remote as well as on-site. With the addition of Cherwell to our group
we can offer an even broader, while specialised portfolio across the
geographies we are active in. This complementary offering opens
exciting growth opportunities for our subsidiaries in the adjacent
countries and our strong distribution partners network.”
Cherwell Laboratories Ltd
OX26 4XB BICESTER, United Kingdom
Gerresheimer and Aptar Digital Health
collaborate to develop integrated
solution for cancer therapy
“Combining our efforts opens up new exciting possibilities for optimizing
the respective drug therapy and improving the quality of life
for cancer patients”, said Daniel Diezi, Vice President Digitalization
& New Business Models at Gerresheimer. “This collaboration in
oncology will lay the groundwork for Aptar Digital Health and Gerresheimer
to potentially expand into other therapeutic areas in the
future.”
“We are honored to collaborate with Gerresheimer, a global industrial
partner in drug delivery devices,” said Sai Shankar, President
of Aptar Digital Health. “By combining our collective and proprietary
expertise in device and software engineering, we believe this collaboration
has the potential to deliver innovative solutions for patients,
healthcare providers and the healthcare industry.”
Enhancing patient experience
Both companies believe that patient experience in oncology can
be improved with innovative subcutaneous injection devices and
digital platforms. For pharmaceutical companies, this collaboration
is an opportunity to offer a patient-centric solution, and tackle challenges
such as treatment interruptions or discontinuations related
to administration issues or adverse effects. It also supports the transition
from intravenous to subcutaneous administration of oncology
drugs.
Support and accompaniment of immunotherapies
The integrated solution will first be designed for targeted anticancer
therapies such as PD-1/PDL-1, CTLA-4, with the potential to
expand to all therapies delivered subcutaneously.
Gerresheimer AG
D 40468 Düsseldorf
www.reinraum.de | www.cleanroom-online.com NEWSLETTER | Edition EN 02-2024
page 14/23